ovalbumin and Pulmonary-Disease--Chronic-Obstructive

elbion (formerly ASTA Medica) and GlaxoSmithKline are developing an inhaled formulation of AWD-12-281 for the potential treatment of chronic obstructive pulmonary disease (COPD). By May 2005, phase II trials of this 5-hydroxyindole PDE4 inhibitor for COPD were ongoing.

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Inhalation; Administration, Topical; Amides; Aminopyridines; Animals; Benzamides; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dermatitis, Atopic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Indoles; Inflammation; Lipopolysaccharides; Ovalbumin; Phosphodiesterase Inhibitors; Psoriasis; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Diseases; Structure-Activity Relationship

Inflammatory airway diseases, such as asthma, cystic fibrosis (CF), and chronic obstructive pulmonary disease (COPD), are characterized by mucus hypersecretion and airway plugging. In both CF and asthma, enhanced expression of the Ca2+-activated Cl- channel TMEM16A is detected in mucus-producing club/goblet cells and airway smooth muscle. TMEM16A contributes to mucus hypersecretion and bronchoconstriction, which are both inhibited by blockers of TMEM16A, such as niflumic acid. Here we demonstrate that the FDA-approved drug niclosamide, a potent inhibitor of TMEM16A identified by high-throughput screening, is an inhibitor of both TMEM16A and TMEM16F. In asthmatic mice, niclosamide reduced mucus production and secretion, as well as bronchoconstriction, and showed additional antiinflammatory effects. Using transgenic asthmatic mice, we found evidence that TMEM16A and TMEM16F are required for normal mucus production/secretion, which may be due to their effects on intracellular Ca2+ signaling. TMEM16A and TMEM16F support exocytic release of mucus and inflammatory mediators, both of which are blocked by niclosamide. Thus, inhibition of mucus and cytokine release, bronchorelaxation, and reported antibacterial effects make niclosamide a potentially suitable drug for the treatment of inflammatory airway diseases, such as CF, asthma, and COPD.

Topics: Animals; Anoctamins; Anti-Inflammatory Agents; Asthma; Bronchi; Cell Line, Tumor; Cystic Fibrosis; Disease Models, Animal; Drug Repositioning; Goblet Cells; HEK293 Cells; Humans; Mice; Mice, Knockout; Mice, Transgenic; Mucus; Niclosamide; Ovalbumin; Pulmonary Disease, Chronic Obstructive; Signal Transduction

Asthma and chronic obstructive pulmonary disease (COPD), chronic airway inflammatory diseases characterized by airflow limitation, have different etiologies and pathophysiologies. Asthma-COPD Overlap (ACO) has recently been used for patients with mixed asthma and COPD. The pathophysiological mechanisms of ACO have not been clearly understood due to the lack of an appropriate murine model. To investigate its pathophysiology, we examined a murine model by allergen challenge in surfactant protein-D (SP-D)-deficient mice that spontaneously developed pulmonary emphysema. SP-D-deficient mice were sensitized and challenged by ovalbumin (OVA). Lungs and bronchoalveolar lavage fluid (BALF) were collected for analysis, and static lung compliance and airway hyperresponsiveness (AHR) were measured 48 h after the last OVA challenge. In SP-D-deficient, naïve, or OVA-challenged mice, the mean linear intercept and static lung compliance were increased compared with wild-type (WT) mice. There was no significant difference in goblet cell hyperplasia and the gene expression of Mucin 5AC (MUC5AC) between SP-D-deficient and WT OVA-challenged mice. In SP-D-deficient OVA-challenged mice, airway hyperresponsiveness was significantly enhanced despite the lower eosinophil count and the concentration of interleukin (IL)-5 and IL-13 in BALF compared with WT OVA-challenged mice at 120 ventilations per minute. When mice were ventilated at a lower ventilation frequency of 100 ventilations per minute, elevated airway hyperresponsiveness in SP-D-deficient OVA-challenged mice was diminished. This model of emphysematous change with allergic airway inflammation raises the possibility that frequency-dependent airway hyperresponsiveness may be involved in the pathophysiology of ACO.

Topics: Animals; Asthma; Disease Models, Animal; Hypersensitivity; Inflammation; Mice; Mice, Inbred C57BL; Mice, Knockout; Ovalbumin; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Pulmonary Surfactant-Associated Protein D; Respiratory Hypersensitivity

Conventional motor nerve conduction studies are usually normal in early and mild carpal tunnel syndrome (CTS). Single-fiber electromyography (SFEMG) measures the mean consecutive difference (MCD) as an expression of the variability in impulse transmission over the motor endplates and along the nerve fibers distally to the last branching point and along the muscle fibers.Application of concentric needle SFEMG in a group of CTS patients who showed pure sensory abnormalities in nerve conduction studies to examine for subclinical motor involvement.. Thirty CTS patients having only sensory involvement proved clinically and by conventional electrophysiological studies were included in addition to 30 control subjects. Concentric needle SFEMG was performed to the abductor pollicis brevis (APB), abductor digiti minimi (ADM), and extensor digitorum communis (EDC) muscles.. The results suggest the presence of a subclinical motor median neuropathy at the wrist in patients with early and mild carpal tunnel syndrome and highlight the validity of the concentric needle SFEMG in early neuropathies.. PACTR201802002971380 registered 12 February 2018, retrospectively registered.. Severely acidotic COPD patients had a poorer short- and long-term prognosis compared with mild-to-moderate acidotic COPD patients if acute and chronic hypoxemia was predominant.

Topics: Acid-Base Equilibrium; Acidosis; Aged; Animals; Caproates; Chi-Square Distribution; Chromatography, Gel; Comorbidity; Delayed-Action Preparations; Drug Carriers; Drugs, Chinese Herbal; Female; Hospitals, Teaching; Humans; Hypoglossal Nerve; Hypoxia; Intensive Care Units; Kaplan-Meier Estimate; Length of Stay; Logistic Models; Magnetic Resonance Spectroscopy; Male; Medicine, Chinese Traditional; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Middle Aged; Nanoparticles; NIH 3T3 Cells; Ovalbumin; Oxygen Inhalation Therapy; Patient Discharge; Polyesters; Polyethylene Glycols; Polymerization; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Respiration, Artificial; Respiratory System; Retrospective Studies; Risk Factors; Severity of Illness Index; Snoring; Spectroscopy, Fourier Transform Infrared; Tertiary Care Centers; Time Factors; Tin; Treatment Outcome

We have previously reported that GPD-1116, an inhibitor of phosphodiesterase (PDE) 4, exhibits anti-inflammatory effects in a model of cigarette smoke-induced emphysema in senescence-accelerated P1 mice. In the present study, we further characterized the pharmacological profile of GPD-1116 in several experiments in vitro and in vivo. GPD-1116 and its metabolite GPD-1133 predominantly inhibited not only human PDE4, but also human PDE1 in vitro. Moreover, GPD-1116 was effective in several disease models in animals, including acute lung injury, chronic obstructive pulmonary disease (COPD), asthma and pulmonary hypertension; the effective doses of GPD-1116 were estimated to be 0.3-2 mg/kg in these models. With regard to undesirable effects known as class effects of PDE4 inhibitors, GPD-1116 showed suppression of gastric emptying in rats and induction of emesis in dogs, but showed no such suppression of rectal temperature in rats, and these side effects of GPD-1116 seemed to be less potent than those of roflumilast. These results suggested that GPD-1116 could be a promising therapeutic agent for the treatment of inflammatory pulmonary diseases. Furthermore, the inhibitory effects of GPD-1116 for PDE1 might be associated with its excellent pharmacological profile. However, the mechanisms through which PDE1 inhibition contributes to these effects should be determined in future studies.

Topics: Acute Lung Injury; Animals; Antigens; Asthma; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclic Nucleotide Phosphodiesterases, Type 4; Dogs; Eosinophilia; Female; Gastric Emptying; Guinea Pigs; Hypertension, Pulmonary; Lipopolysaccharides; Lung; Male; Naphthyridines; Ovalbumin; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Rats, Sprague-Dawley; Smoke; Vomiting

Heparanase is an endo-β-glucuronidase that specifically cleaves heparan sulfate proteoglycans in the extracellular matrix. Expression of this enzyme is increased in several pathological conditions including inflammation. We have investigated the role of heparanase in pulmonary inflammation in the context of allergic and non-allergic pulmonary cell recruitment using heparanase knockout (Hpa-/-) mice as a model. Following local delivery of LPS or zymosan, no significant difference was found in the recruitment of neutrophils to the lung between Hpa-/- and wild type (WT) control. Similarly neutrophil recruitment was not inhibited in WT mice treated with a heparanase inhibitor. However, in allergic inflammatory models, Hpa-/- mice displayed a significantly reduced eosinophil (but not neutrophil) recruitment to the airways and this was also associated with a reduction in allergen-induced bronchial hyperresponsiveness, indicating that heparanase expression is associated with allergic reactions. This was further demonstrated by pharmacological treatment with a heparanase inhibitor in the WT allergic mice. Examination of lung specimens from patients with different severity of chronic obstructive pulmonary disease (COPD) found increased heparanase expression. Thus, it is established that heparanase contributes to allergen-induced eosinophil recruitment to the lung and could provide a novel therapeutic target for the development of anti-inflammatory drugs for the treatment of asthma and other allergic diseases.

Topics: Animals; Enzyme Inhibitors; Female; Gene Deletion; Glucuronidase; Humans; Hypersensitivity; Immunization; Inflammation; Lung; Male; Mice, Inbred BALB C; Middle Aged; Ovalbumin; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests

Optimization of lead compound 1, through extensive use of structure-based design and a focus on PI3Kδ potency, isoform selectivity, and inhaled PK properties, led to the discovery of clinical candidates 2 (GSK2269557) and 3 (GSK2292767) for the treatment of respiratory indications via inhalation. Compounds 2 and 3 are both highly selective for PI3Kδ over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation.

Topics: Administration, Inhalation; Animals; Asthma; Female; Humans; Indazoles; Indoles; Isoenzymes; Male; Microsomes; Molecular Docking Simulation; Ovalbumin; Oxazoles; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Pneumonia; Pulmonary Disease, Chronic Obstructive; Rabbits; Rats; Rats, Sprague-Dawley; Respiratory Tract Diseases; Stereoisomerism; Structure-Activity Relationship; Sulfonamides; Th2 Cells

The main objective of this study was to improve the safety and oxidative stability of glycerol monooleate (GMO)-based dry-emulsion (DE) formulation containing cyclosporine A (CsA) for inhalation therapy. GMO or highly purified GMO (hpGMO) was used as surfactant for the DE formulations (GMO/DE or hpGMO/DE), the toxicological and physicochemical properties of which were characterized with a focus on oxidative stability, in vitro/in vivo toxicity, and dissolution property. Incubation of GMO at oxidation accelerating conditions for 10 days at 60°C resulted in the formation of lipid peroxides as evidenced by increased malondialdehyde (111 μmol/mg); however, hpGMO samples exhibited increase of only 20.7 μmol/mg in malondialdehyde level. No significant acute cytotoxicity was observed in rat alveolar L2 cells exposed to hpGMO (0.28mM), and intratracheal administration of hpGMO powder in rats did not cause an increase of the plasma LDH level. The hpGMO/DE exhibited marked improvement in dissolution behavior of CsA, and stable fine micelles with a mean diameter of 320 nm were formed when suspended in water. A respirable powder formulation of hpGMO/DE (hpGMO/DE-RP) was newly prepared, and its in vitro inhalation property and in vivo efficacy were also evaluated. The hpGMO/DE-RP exhibited high dispersibility in laser diffraction analysis and significantly improved potency to attenuate recruitment of inflammatory cells into airway and thickening of airway wall in an animal model. Thus, the strategic use of hpGMO would improve oxidative stability and local toxicity compared with a GMO-based DE formulation, and its application to RP formulation could be a promising approach for effective inhalation therapy.

Topics: Animals; Anti-Inflammatory Agents; Antigens; Asthma; Cell Line; Cyclosporine; Disease Models, Animal; Emulsions; Glycerides; Male; Ovalbumin; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Sprague-Dawley; Respiratory Therapy; Surface-Active Agents

The multidrug resistance protein 4 (Mrp4) is an ATP-binding cassette transporter that is capable of exporting the second messenger cAMP from cells, a process that might regulate cAMP-mediated anti-inflammatory processes. However, using LPS- or cigarette smoke (CS)-inflammation models, we found that neutrophil numbers in the bronchoalveolar lavage fluid (BALF) were similar in Mrp4(-/-) and Mrp4(+/+) mice treated with LPS or CS. Similarly, neutrophil numbers were not reduced in the BALF of LPS-challenged wt mice after treatment with 10 or 30 mg/kg of the Mrp1/4 inhibitor MK571. The absence of Mrp4 also had no impact on the influx of eosinophils or IL-4 and IL-5 levels in the BALF after OVA airway challenge in mice sensitized with OVA/alum. LPS-induced cytokine release in whole blood ex vivo was also not affected by the absence of Mrp4. These data clearly suggest that Mrp4 deficiency alone is not sufficient to reduce inflammatory processes in vivo. We hypothesized that in combination with PDE4 inhibitors, used at suboptimal concentrations, the anti-inflammatory effect would be more pronounced. However, LPS-induced neutrophil recruitment into the lung was no different between Mrp4(-/-) and Mrp4(+/+) mice treated with 3 mg/kg Roflumilast. Finally, the single and combined administration of 10 and 30 mg/kg MK571 and the specific breast cancer resistance protein (BCRP) inhibitor KO143 showed no reduction of LPS-induced TNFα release into the BALF compared to vehicle treated control animals. Similarly, LPS-induced TNFα release in murine whole blood of Mrp4(+/+) or Mrp4(-/-) mice was not reduced by KO143 (1, 10 µM). Thus, BCRP seems not to be able to compensate for the absence or inhibition of Mrp4 in the used models. Taken together, our data suggest that Mrp4 is not essential for the recruitment of neutrophils into the lung after LPS or CS exposure or of eosinophils after allergen exposure.

Topics: Adenosine; Allergens; Animals; Asthma; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bronchoalveolar Lavage Fluid; Cyclic AMP; Cytokines; Diketopiperazines; Eosinophils; Heterocyclic Compounds, 4 or More Rings; Lipopolysaccharides; Lung; Mice; Multidrug Resistance-Associated Proteins; Neutrophils; Ovalbumin; Phosphodiesterase 4 Inhibitors; Propionates; Pulmonary Disease, Chronic Obstructive; Quinolines; Rolipram; Smoking; Th2 Cells; Time Factors

Goblet cell hyperplasia (GCH) and mucous hypersecretion are common pathological features of chronic pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and cystic fibrosis. Despite numerous studies, the molecular basis for this condition remains elusive. Gab2 is a member of the Dos/Gab subfamily scaffolding molecules and plays important roles in regulating growth, differentiation, and inflammation. We found that an elevated level of Gab2 correlates with up-regulated mucus in airway epithelia from patients with lung cancer or COPD, suggesting the potential involvement of Gab2 in pathological lesions in lungs. Knockdown of Gab2 in human airway epithelial cells in vitro decreases IL-13-induced expression of mucin genes. To address the in vivo role of Gab2 in lungs, Gab2-knockout (Gab2(-/-)) mice were sensitized and challenged with ovalbumin (OVA). Further analysis of lungs in an OVA-induced allergy model suggested that GCH and mucus production are remarkably reduced in Gab2(-/-) mice. Mechanistically, Gab2 positively regulates IL-13-induced activation of TYK2/STAT6 by decreasing SOCS3-mediated degradation of TYK2. Together, we define a novel role for Gab2 in mediating mucin gene expression and GCH; these findings have important implications for the pathogenesis and therapy of airway inflammatory diseases.

Topics: Adaptor Proteins, Signal Transducing; Animals; Epithelial Cells; Gene Expression Regulation; Goblet Cells; Humans; Hyperplasia; Hypersensitivity; Interleukin-13; Lung; Lung Neoplasms; Mice; Mice, Knockout; Mucins; Mucus; Ovalbumin; Phosphoproteins; Pulmonary Disease, Chronic Obstructive; Respiratory Mucosa; STAT6 Transcription Factor; TYK2 Kinase

Tranilast (TL) has been clinically used for the treatment of airway inflammatory diseases, although the clinical use of TL is limited because of its poor solubility and systemic side effects. To overcome these drawbacks, a novel respirable powder of TL (CSD/TL-RP) for inhalation therapy was developed using nanocrystal solid dispersion of TL (CSD/TL). Stability study on CSD/TL-RP was carried out with a focus on inhalation performance. Even after 6 months of storage at room temperature, there were no significant morphological changes in micronized particles on the surface of carrier particles as compared with that before storage. Cascade impactor analyses on CSD/TL-RP demonstrated high inhalation performance with emitted dose and fine particle fraction (FPF) of ca. 98% and 60%, respectively. Long-term storage of CSD/TL-RP resulted in only a slight decrease in FPF value (ca. 54%). Inhaled CSD/TL-RP could attenuate antigen-induced inflammatory events in rats, as evidenced by marked reduction of granulocytes in bronchoalveolar lavage fluid and inflammatory biomarkers such as eosinophil peroxidase, myeloperoxidase, and lactate dehydrogenase. These findings were consistent with decreased expression levels of mRNAs for nuclear factor-kappa B and cyclooxygenase-2, typical inflammatory mediators. Given these findings, inhalable TL formulation might be an interesting alternative to oral therapy for the treatment of asthma and other airway inflammatory diseases with sufficient dispersing stability.

Topics: Administration, Inhalation; Animals; Anti-Allergic Agents; Asthma; Biomarkers; Bronchoalveolar Lavage Fluid; Cyclooxygenase 2; Drug Compounding; Drug Stability; Dry Powder Inhalers; Granulocytes; Inflammation Mediators; Lung; Male; Nanoparticles; NF-kappa B; ortho-Aminobenzoates; Ovalbumin; Powders; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Sprague-Dawley; RNA, Messenger

Several epidemiologic studies have found that smokers with chronic obstructive pulmonary disease (COPD), an inflammatory disease of the lung, have an increased risk of lung cancer compared with smokers without COPD. We have shown a causal role for COPD-like airway inflammation in lung cancer promotion in the CCSP(Cre)/LSL-K-ras(G12D) mouse model (CC-LR). In contrast, existing epidemiologic data do not suggest any definite association between allergic airway inflammation and lung cancer. To test this, CC-LR mice were sensitized to ovalbumin (OVA) and then challenged with an OVA aerosol weekly for 8 weeks. This resulted in eosinophilic lung inflammation associated with increased levels of T helper 2 cytokines and mucous metaplasia of airway epithelium, similar to what is seen in asthmatic patients. However, this type of inflammation did not result in a significant difference in lung surface tumor number (49 ± 9 in OVA vs. 52 ± 5 in control) in contrast to a 3.2-fold increase with COPD-like inflammation. Gene expression analysis of nontypeable Haemophilus influenzae (NTHi)-treated lungs showed upregulation of a different profile of inflammatory genes, including interleukin 6 (IL-6), compared with OVA-treated lungs. Therefore, to determine the causal role of cytokines that mediate COPD-like inflammation in lung carcinogenesis, we genetically ablated IL-6 in CC-LR mice. This not only inhibited intrinsic lung cancer development (1.7-fold) but also inhibited the promoting effect of extrinsic COPD-like airway inflammation (2.6-fold). We conclude that there is a clear specificity for the nature of inflammation in lung cancer promotion, and IL-6 has an essential role in lung cancer promotion.

Topics: Aerosols; Animals; Biomarkers, Tumor; Cytokines; Disease Models, Animal; Female; Gene Expression Profiling; Haemophilus Infections; Haemophilus influenzae; Immunoenzyme Techniques; Integrases; Interleukin-6; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Oligonucleotide Array Sequence Analysis; Ovalbumin; Pneumonia; Proto-Oncogene Proteins p21(ras); Pulmonary Disease, Chronic Obstructive; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Th2 Cells; Tumor Burden; Uteroglobin

Hesperetin was reported to selectively inhibit phosphodiesterase 4 (PDE4). While hesperetin-7,3'-O-dimethylether (HDME) is a synthetic liposoluble hesperetin. Therefore, we were interested in investigating its selectivity on PDE4 and binding ability on high-affinity rolipram-binding sites (HARBs) in vitro, and its effects on ovalbumin-induced airway hyperresponsiveness in vivo, and clarifying its potential for treating asthma and chronic obstructive pulmonary disease (COPD).. PDE1~5 activities were measured using a two-step procedure. The binding of HDME on high-affinity rolipram-binding sites was determined by replacing 2 nM [3H]-rolipram. AHR was assessed using the FlexiVent system and barometric plethysmography. Inflammatory cells were counted using a hemocytometer. Cytokines were determined using mouse T helper (Th)1/Th2 cytokine CBA kits, and total immunoglobulin (Ig)E or IgG2a levels were done using ELISA method. Xylazine (10 mg/kg)/ketamine (70 mg/kg)-induced anesthesia was performed.. HDME revealed selective phosphodiesterase 4 (PDE4) inhibition with a therapeutic (PDE4H/PDE4L) ratio of 35.5 in vitro. In vivo, HDME (3~30 μmol/kg, orally (p.o.)) dose-dependently and significantly attenuated the airway resistance (RL) and increased lung dynamic compliance (Cdyn), and decreased enhanced pause (Penh) values induced by methacholine in sensitized and challenged mice. It also significantly suppressed the increases in the numbers of total inflammatory cells, macrophages, lymphocytes, neutrophils, and eosinophils, and levels of cytokines, including interleukin (IL)-2, IL-4, IL-5, interferon-γ, and tumor necrosis factor-α in bronchoalveolar lavage fluid (BALF) of these mice. In addition, HDME (3~30 μmol/kg, p.o.) dose-dependently and significantly suppressed total and ovalbumin-specific immunoglobulin (Ig)E levels in the BALF and serum, and enhanced IgG2a level in the serum of these mice.. HDME exerted anti-inflammatory effects, including suppression of AHR, and reduced expressions of inflammatory cells and cytokines in this murine model, which appears to be suitable for studying the effects of drugs on atypical asthma and COPD, and for screening those on typical asthma. However, HDME did not influnce xylazine/ketamine-induced anesthesia. Thus HDME may have the potential for use in treating typical and atypical asthma, and COPD.

Topics: Animals; Asthma; Binding Sites; Blood Cell Count; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Disease Models, Animal; Female; Guinea Pigs; Hesperidin; Immunoglobulins; Male; Mice; Mice, Inbred BALB C; Ovalbumin; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Rolipram

This study was directed toward the development of novel ovalbumin dry powder inhalation system (OVA-DPI) for preparing experimental animal models of chronic obstructive pulmonary disease, with the aim of aiding the drug discovery. OVA-DPI, prepared with jet mill, showed high dispersion and emission from capsule as evaluated by cascade impactor. Based on the results from long term stability studies employing scanning electron microscopy, UPLC/ESI-MS analysis, powder X-ray diffraction and TG/DTA analyses, the OVA-DPI, stored at room temperature, was found to be stable for more than 3 years as evidenced by no significant degradation and crystal polymorphism. Intratracheal administration of OVA-DPI in OVA-sensitized rats resulted in 11-fold increase of infiltrated granulocytes, especially neutrophil, which would be characteristics of severe asthma/COPD symptoms. Of all plasma biomarkers monitored, myeloperoxidase activity and lactate dehydrogenase leakage into blood seemed to be sensitive indicators of lung injury in this model. In addition, biphasic increase of LDH was observed with peak responses at 3 and 24h after antigen challenge, suggesting that OVA-DPI could cause both acute and delayed inflammatory reactions. Upon these findings, OVA-DPI can be useful and reproducible research tool for the development of experimental asthma/COPD model.

Topics: Administration, Inhalation; Animals; Biomarkers; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Differential Thermal Analysis; L-Lactate Dehydrogenase; Lung; Male; Microscopy, Electron, Scanning; Nephelometry and Turbidimetry; Ovalbumin; Particle Size; Peroxidase; Powders; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Serine Proteinase Inhibitors; Thermogravimetry; X-Ray Diffraction

Diagnosis and therapy of chronic inflammatory lung disease is limited by the need for individualized biomarkers that provide insight into pathogenesis. Herein we show that mouse models of chronic obstructive lung disease exhibit an increase in lung chitinase production but cannot predict which chitinase family member may be equivalently increased in humans with corresponding lung disease. Moreover, we demonstrate that lung macrophage production of chitinase 1 is selectively increased in a subset of subjects with severe chronic obstructive pulmonary disease, and this increase is reflected in plasma levels. The findings provide a means to noninvasively track alternatively activated macrophages in chronic lung disease and thereby better differentiate molecular phenotypes in heterogeneous patient populations.

Topics: Adipokines; Aged; Animals; Biomarkers; Chitinase-3-Like Protein 1; Chitinases; Disease Models, Animal; Gene Expression Profiling; Glycoproteins; Humans; Interleukin-13; Lectins; Lung; Macrophages, Alveolar; Mice; Mice, Inbred BALB C; Middle Aged; Ovalbumin; Phylogeny; Pulmonary Disease, Chronic Obstructive; RNA, Messenger; Sequence Homology, Amino Acid; Severity of Illness Index; Smoking; Species Specificity

Neurokinins are known to induce neurogenic inflammation related to respiratory diseases. The effects of CS-003 ([1-{2-[(2R)-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl}spiro[benzo[c]thiophene-1(3H),4'-piperidine]-(2S)-oxide hydrochloride]), a novel triple neurokinin receptor antagonist, on several respiratory disease models were evaluated in guinea pigs. As we have already shown that CS-003 is intravenously effective, we first determined if CS-003 was orally effective. CS-003 dose-dependently inhibited substance P-induced tracheal vascular hyperpermeability, neurokinin A- and neurokinin B-induced bronchoconstriction with ID(50) values of 3.6, 1.3 and 0.89 mg/kg (p.o.), respectively. CS-003 (10 mg/kg, p.o.) inhibited the number of coughs induced by capsaicin aerosol (P<0.01) and the antitussive effect was comparable to that of codeine. CS-003 (10 mg/kg, p.o.) also inhibited airway hyperresponsiveness to methacholine chloride in ovalbumin-induced asthma models (P<0.01), a milder one and a severer one. On the other hand, montelukast (10 mg/kg, p.o.), a leukotriene receptor antagonist, significantly inhibited the hyperresponsiveness only in the milder model (P<0.05). In an ovalbumin-induced rhinitis model, oral administration of CS-003 inhibited nasal blockade in a dose-dependent manner and the inhibitory effect was comparable to that of dexamethasone (10 mg/kg, p.o.). CS-003 (i.v.) also dose-dependently inhibited cigarette smoke-induced bronchoconstriction, tracheal vascular hyperpermeability and mucus secretion. These data show that CS-003, a potent orally active triple neurokinin receptor antagonist, may be useful for the treatment of respiratory diseases associated with neurokinins, such as allergic asthma, allergic rhinitis, chronic obstructive pulmonary disease and cough.

Topics: Administration, Oral; Animals; Asthma; Bronchoconstriction; Capillary Permeability; Capsaicin; Cough; Cyclic S-Oxides; Disease Models, Animal; Guinea Pigs; Male; Morpholines; Mucus; Nicotiana; Ovalbumin; Pulmonary Disease, Chronic Obstructive; Receptors, Tachykinin; Respiratory Tract Diseases; Rhinitis; Smoke; Trachea

Current techniques to evaluate the efficacy of potential treatments for airways diseases in small animal models are generally invasive and terminal. In this contribution we illustrate the usefulness of magnetic resonance imaging (MRI) to obtain anatomical and functional information of the lung, with the scope of developing a non-invasive approach for the routine testing of drugs in rat models of airways diseases. With MRI, the disease progression can be followed in the same animal. Thus, a significant reduction in the number of animals used for experimentation is achieved, as well as minimal interference with their well-being and physiological status. In addition, MRI has the potential to shorten the duration of the observation period after disease onset since the technique is able to detect changes before these are reflected in invasively determined parameters of inflammation.

Topics: Allergens; Animals; Bronchoalveolar Lavage Fluid; Magnetic Resonance Imaging; Ovalbumin; Pulmonary Disease, Chronic Obstructive; Rats; Respiration Disorders

Airway remodeling is a characteristic feature of asthma that leads to chronic irreversible airway obstruction. Fibrosis in the basement membrane region is a hallmark of remodeling in asthma that is not found in other diseases. In the outlined studies, we investigated the relationship between relaxin and airway fibrosis in asthma using acute and chronic models of allergic airway disease. These studies confirm a critical role for relaxin, in the regulation of collagen deposition in the airway/lung in animal models of allergic airway disease.

Topics: Acute Disease; Animals; Disease Models, Animal; Hypersensitivity; Mice; Mice, Knockout; Ovalbumin; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; Relaxin

Proton signals from lung parenchyma were detected with the use of a gradient-echo sequence to noninvasively obtain information on pulmonary function in models of airway diseases in rats. Initial measurements carried out in artificially ventilated control rats revealed a highly significant negative correlation between the parenchymal signal and the partial pressure of oxygen (pO2) in the blood, for different amounts of oxygen administered. The magnitude of the signal intensity variations caused by changes in the oxygen concentration was larger than expected solely from the paramagnetic properties of molecular oxygen. Inhomogeneous line-broadening induced by lung inflation may explain the observed signal amplification. Experiments carried out in spontaneously breathing animals challenged with allergen or endotoxin revealed parenchymal signal changes that reflected the oxygenation status of the lungs and were consistent with airway remodeling or hyporesponsiveness. The results suggest that proton MRI of parenchymal tissue is a sensitive tool for probing the functional status of the lung in rat models of respiratory diseases. The method is complementary to the recently described noninvasive assessment by MRI of pulmonary inflammation in small rodents. Overall, these techniques provide invaluable information for profiling anti-inflammatory drugs in models of airway diseases.

Topics: Allergens; Analysis of Variance; Animals; Endotoxins; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Ovalbumin; Pulmonary Disease, Chronic Obstructive; Pulmonary Edema; Rats; Rats, Inbred BN; Reproducibility of Results; Respiration; Respiration, Artificial

A detailed analysis has been carried out of the correlation between the signals detected by MRI in the rat lung after allergen or endotoxin challenge and parameters of inflammation determined in the broncho-alveolar lavage (BAL) fluid. MRI signals after allergen correlated highly significantly with the BAL fluid eosinophil number, eosinophil peroxidase activity and protein concentration. Similar highly significant correlations were seen when the anti-inflammatory glucocorticosteroid, budesonide, manifested against allergen. In contrast, following endotoxin challenge, mucus was the sole BAL fluid parameter that correlated significantly with the long lasting signal detected by MRI. Since edema is an integral component of pulmonary inflammation, MRI provides a noninvasive means of monitoring the course of the inflammatory response and should prove invaluable in profiling anti-inflammatory drugs in vivo. Further, the prospect of noninvasively detecting a sustained mucus hypersecretory phenotype in the lung brings an important new perspective to models of chronic obstructive pulmonary diseases.

Topics: Allergens; Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Budesonide; Eosinophil Peroxidase; Inflammation; Lipopolysaccharides; Lung; Magnetic Resonance Imaging; Male; Mucus; Ovalbumin; Peroxidases; Pulmonary Disease, Chronic Obstructive; Pulmonary Edema; Pulmonary Eosinophilia; Rats; Rats, Inbred BN; Respiration